AURA - Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play
- Clearside Biomedical reported positive safety data from phase 1/2a study using SCS microinjector for suprachoroidal delivery in patients with wet age-related macular degeneration.
- Clearside Biomedical and its partner Bausch & Lomb received FDA approval of first suprachoroidal injection drug XIPERE for treatment of patients with macular edema associated with uveitis.
- XIPERE is expected to launch in the 1st half of 2022, and Clearside has already received a $19 million pre-commercial milestone payment for it.
- Other established pharmaceutical companies exploring the use of the SCS microinjector for suprachoroidal delivery of their eye drugs are REGENXBIO and Aura Biosciences.
For further details see:
Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play